Keyphrases
Mantle Cell Lymphoma
98%
Rituximab
80%
Follicular Lymphoma
65%
Relapsed or Refractory
58%
Diffuse Large B-cell Lymphoma (DLBCL)
58%
Overall Survival
49%
Progression-free Survival
48%
Lymphoma
33%
Doxorubicin
32%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
31%
Chronic Lymphocytic Leukemia
28%
Maintenance Rituximab
28%
Prednisone
27%
Bendamustine
27%
Phase II Study
27%
Clinical Trials
27%
Lymphoma Patients
27%
Complete Response
25%
Non-Hodgkin Lymphoma
23%
Cyclophosphamide
23%
Bendamustine-rituximab
22%
Overall Response Rate
21%
Hodgkin Lymphoma
21%
Bortezomib
21%
Indolent non-Hodgkin Lymphoma
19%
Confidence Interval
19%
R-CHOP
19%
Wisconsin
18%
High Risk
17%
Chemotherapy
17%
Oncological Networks
16%
Initial Treatment
15%
Eastern Cooperative Oncology Group
15%
Network Studies
14%
Clinical Outcomes
14%
Brentuximab Vedotin
14%
Lenalidomide
14%
Older Patients
13%
Indolent Lymphoma
13%
Chemoimmunotherapy
12%
Low Tumor Burden
12%
Duration of Response
12%
Peripheral T-cell Lymphoma
12%
Hazard Ratio
12%
Frontline Therapy
11%
Treatment Strategy
11%
Event-free Survival
11%
Response Rate
11%
Ibrutinib
11%
Newly Diagnosed
11%
Medicine and Dentistry
Mantle Cell Lymphoma
83%
Rituximab
82%
Diffuse Large B-Cell Lymphoma
55%
Overall Survival
54%
Progression Free Survival
46%
Non-Hodgkin Lymphoma
45%
Follicular Lymphoma
42%
Diseases
40%
Oncology
37%
Clinical Trial
36%
Neoplasm
29%
Bendamustine
28%
Doxorubicin
26%
Hodgkin's Lymphoma
26%
B-Cell Chronic Lymphocytic Leukemia
23%
Vincristine
21%
B Cell
20%
Cyclophosphamide
20%
Prednisone
18%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
16%
Lymphocytic Lymphoma
16%
Arm
15%
B-Cell Lymphoma
13%
Adriamycin Bleomycin Vinblastine Dacarbazine
12%
Bortezomib
12%
Peripheral T-Cell Lymphoma
12%
Malignant Neoplasm
11%
Stem Cell Transplant
11%
Positron Emission Tomography
11%
Chemoimmunotherapy
11%
Lenalidomide
11%
Biological Marker
11%
Ibrutinib
11%
Brentuximab Vedotin
10%
Classical Hodgkin Lymphoma
10%
Cohort Analysis
10%
Hazard Ratio
10%
Drug Megadose
9%
Adverse Event
9%
Cytarabine
9%
Hematopoietic Cell
9%
Autologous Stem Cell Transplantation
9%
Event Free Survival
8%
Phosphoinositide 3-Kinase
8%
MALT Lymphoma
8%
Cell Transplantation
8%
Electrocorticography
8%
Cancer
7%
Hematologic Malignancy
7%
Chimeric Antigen Receptor T-Cell Immunotherapy
7%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Mantle Cell Lymphoma
70%
Follicular Lymphoma
52%
Nonhodgkin Lymphoma
51%
Diffuse Large B Cell Lymphoma
44%
Bendamustine
40%
Progression Free Survival
39%
Overall Survival
38%
Diseases
37%
Cyclophosphamide
28%
Vincristine
27%
Doxorubicin
26%
Chemotherapy
25%
Clinical Trial
25%
Prednisone
24%
Chronic Lymphatic Leukemia
24%
Neoplasm
22%
Bortezomib
18%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
15%
Remission
14%
Lymphocytic Lymphoma
13%
Adverse Event
12%
Hodgkin Disease
12%
Lenalidomide
11%
Malignant Neoplasm
11%
Phosphatidylinositol 3 Kinase
10%
Etoposide
10%
Ibrutinib
8%
Neutropenia
8%
B Cell Lymphoma
8%
Zanubrutinib
8%
Ibritumomab Tiuxetan
8%
Event Free Survival
7%
Loncastuximab Tesirine
7%
Idelalisib
7%
Venetoclax
7%
Large Cell Lymphoma
6%
Pharmacokinetics
6%
Peripheral T Cell Lymphoma
6%
Survival Rate
6%
Tolerability
6%
Yttrium 90
6%
Duvelisib
6%
Combination Therapy
6%
Hematologic Malignancy
5%
Minimal Residual Disease
5%
Methotrexate
5%
Diarrhea
5%
Brentuximab Vedotin
5%
Biological Marker
5%